Replies to post #243210 on Amarin Corp Plc (AMRN)

[amarinbullfromchicago]

And they would have to sell in the next year...I don’t think they’ll get anywhere near 10-20b for Europe buyout in the next year, and they cannot do it themselves

[couldbebetter]

HDGabor, I think your $600 per year per patient revenue estimate for the
sale of Vascepa in Europe is far too low.

1. The price of AMRN will be negotiated country by country, and the
efficacy of the drug is taken into consideration.

2. Vascepa will have 11 years without any other branded drug or
generic drug competition. Thus the price may start out at a
higher price than what Vascepa receives in the US in that
it had to be priced lower because it was competing against a
generic Lovaza before R-I results were known.

3. Vascepa in Europe is unique. It will not only be the only
Omega-3 approved for reimbursement but will be labeled for
Cardiovascular Disease.

4. When Vascepa is launched in Europe, most likely in Germany,
I believe it will be priced to produce around $2000 per year,
per patient. If it were priced to produce only $600 per year
that would be only $50 per month...that number seems way too low
for a branded drug with no competition.